Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?

Oncology

Volumn 68, Issue 2-3, 2005, Pages 115-121

  Kasper, Bernd ^a   Ho, Anthony D ^a   Egerer, Gerlinde ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bone sarcomas; High dose chemotherapy; Review; Soft tissue sarcomas; Stem cell support

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; SAMARIUM 153;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHONDROSARCOMA; CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; EWING SARCOMA; HISTOLOGY; HUMAN; INTERMETHOD COMPARISON; LEIOMYOSARCOMA; LEUKOPENIA; LIPOSARCOMA; MONOTHERAPY; NERVE SHEATH TUMOR; NEUTROPENIA; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; STEM CELL TRANSPLANTATION; SURVIVAL TIME; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; ADOLESCENT; ADULT; BONE MARROW CANCER; BONE TUMOR; DRUG ADMINISTRATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LIVER TUMOR; LUNG TUMOR; MALE; MIDDLE AGED; RETROPERITONEAL TUMOR; RETROSPECTIVE STUDY; SARCOMA; SKIN TUMOR; SURVIVAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW NEOPLASMS; BONE NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OSTEOSARCOMA; RETROPERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; SARCOMA; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 23844551353     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085704     Document Type: Review

References (35)

1. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T: Prognostic factors in advanced soft tissue sarcoma: An analysis of 2185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 1999;17:150-157.
2. Edmonson JH, Ryan LM, Blum RG, Brooks JS, Shiraki M, Frytak S, Parkinson DR: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxombicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-1275.
3. Antman KH, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-1285.
4. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, et al: Doxorubicin versus CyVADic versus ifosfamide plus doxorubicin in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-1545.
5. Bui NB, Demaille MC, Chevreau C, Blay JY, Cupissol D, Rios M, Thyss A, Maugard C, Bastit P, Bay JO, Tanguy A, Fargeot P, Lortholary A, Bonichon F: qMAID vs MAID + 25% in adults with advanced soft tissue sarcoma (STS): First results of a randomized study of the FNCLCC Sarcoma Group (abstract 1991). Proc Am Soc Clin Oncol 1998;17:517a.
6. Blay JY, van Glabbeke M, Nielsen OS, van Oosterom AT, Tursz T, Oosterhuis JW, Verweij J: Five-year survivors in patients (pts) with advanced soft tissue sarcoma (ASTS) treated with doxorubicin: A study on 1742 patients (STBSG) (abstract 1973). Proc Am Soc Clin Oncol 1998;17:512a.
7. Standard-Options-Recommandations, vol 1: Sarcome des Tissus Mous et Ostéosarcomes. Paris, Arnette/Blackwell, 1995, pp 1-113.
8. Demetri GD, Elias AD: Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas: Implications for decision making in the clinic. Hematol Oncol Clin North Am 1995;9:765-785.
9. Verweij J, Mouridsen HT, Nielsen OS, Woll PJ, Somers R, van Oosterom AT, van Glabbeke M, Tursz T: The present state of the art in chemotherapy for soft tissue sarcomas in adults: The EORTC point of view. Crit Rev Oncol Hematol 1995;20:193-201.
10. Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt J, Holmes C, Fu YS: Synovial sarcoma: Uniform response of metastases to high dose ifosfamide. Cancer 1994;73:2506-2511.
11. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS: High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies - Dose-response and schedule dependence. J Clin Oncol 1997;15:2378-2384.
12. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J, et al: High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995;13:1600-1608.
13. Saeter G, Alvegard TA, Monge OR, Strander H, Turesson I, Klepp R, Soderberg M, Wist E, Raabe N, Erlanson M, Solheim OP, Hannisdal E: Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma: A Scandinavian Sarcoma Group phase II study. Eur J Cancer 1997;33:1551-1558.
14. Jelic S, Kovcin V, Milanovic N, Babovic N, Kreacic M, Ristovic Z, Vlajic M, Filipovic-Ljeskovic I: Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 1997;33:220-225.
15. Reichardt P, Tilgner J, Hohenberger P, Dorken B: Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study. J Clin Oncol 1998;16:1438-1443.
16. Horowitz ME, Kinsella TJ, Wexler LH, Belasco J, Triche T, Tsokos M, Steinberg SM, McClure L, Longo DL, Steiss RG, et al: Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993;11:1911-1918.
17. Burdach S, Jurgens H, Peters C, Nürnberger W, Mauz-Korholz C, Korholz D, Paulussen M, Pape H, Dilloo D, Koscielniak E, et al: Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993;11:1482-1488.
18. Boulad F, Kernan NA, LaQuaglia MP, Heller G, Lindsley KL, Rosenfield NS, Abramson SJ, Gerald WL, Small TN, Gillio AP, Gulati SC, O'Reilly RJ, Ghavimi F: High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998;16:1697-1706.
19. Fagioli F, Aglietta M, Tienghi A, Ferrari S, Brach del Prever A, Vassallo E, Palmero A, Biasin E, Bacci G, Picci P, Madon E: High-dose chemotherapy in the treatment of relapsed osteosarcoma: An Italian sarcoma group study. J Clin Oncol 2001;20:2150-2156.
20. Sauerbrey A, Bielack S, Kempf-Bielack B, Zoubek A, Paulussen M, Zintl F: High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant 2001;27:933-937.
21. Bokemeyer C, Franzke A, Hartmann JT, Schober C, Arseniev L, Metzner B, Link H, Kanz L, Schmoll HJ: A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997;80:1221-1227.
22. Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, Gonin R, McCauley M, Mazanet R, Schnipper L, Frei E 3rd, et al: Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 1995;15:373-379.
23. Dumontet C, Biron P, Bouffet E, Blay JY, Meckenstock R, Chauvin F, Philip I, Clavel M, Brunat-Mentigny M, Philip T: High dose chemotherapy with ABMT in soft tissue sarcomas: A report of 22 cases. Bone Marrow Transplant 1992;10:405-408.
24. Mesia R, Sola C, Lopez Pousa A, Mendoza L, Bellet M, Andres L, Lopez Lopez JJ: High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas (in Spanish). Rev Clin Esp 1994;194:960-965.
25. Wiklund T, Saeter G, Strander H, Alvegard T, Blomqvist C: The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery: The Scandinavian Sarcoma Group experience. Eur J Cancer 1997;33:357-361.
26. Seynaeve C, Verweij J: High-dose chemotherapy in adult sarcomas: No standard yet. Semin Oncol 1999;26:119-133.
27. Blay JY, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, Biron P: High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 2000;18:3643-3650.
28. Elias AD, Ayasj LJ, Eder JP, Wheeler C, Deary J, Weissman L, Schryber S, Hunt M, Critchlow J, Schnipper L, et al: A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol 1991;9:320-327.
29. Rosti G, Ferrante P, Ledermann J, Leyvraz S, Ladenstein R, Koscileniak E, Crown J, Dazzi C, Cariello A, Marangolo M: High-dose chemotherapy for solid tumors: Results of the EBMT. Crit Rev Oncol Hematol 2002;41:129-140.
30. Reichardt P: High-dose chemotherapy in adult soft tissue sarcoma. Crit Rev Oncol Hematol 2002;41:157-167.
31. Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, Ho AD, Egerer G: High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 2004;34:37-41.
32. Vogt T, Hafner C, Bross K, Bataille F, Jauch K-W, Landthaler M, Andreesen R, Reichle A: Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 2003;98:2251-2256.
33. Reichle A, Vogt T, Bross K, Bataille F, Berand A, Zaiss M, Wagner H, Krause SW, Andreesen R: Pioglitazone and rofecoxib combined with angiostatic scheduling of chemotherapy in second line therapy of advanced melanomas and pre-treated soft-tissue sarcomas. Onkologie 2003;26:V382.
34. Nishida K, Furumatsu T, Takada I, Kawai A, Yoshida A, Kunisada T, Inoue H: Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-gamma. Br J Cancer 2002;86:1303-1309.
35. Masferrer J: Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J 2001;7:S144-S150.